Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus-diphtheria-acellular pertussis-inactivated poliovirus vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tetanus-diphtheria-acellular pertussis-inactivated poliovirus vaccine (Tdap-IPV) is a combination booster vaccine indicated for active immunization against tetanus, diphtheria, pertussis, and poliomyelitis. It is typically administered to adolescents and adults who have previously received a primary vaccination series. The vaccine contains tetanus and diphtheria toxoids, acellular pertussis components (such as pertussis toxoid, filamentous hemagglutinin, and pertactin), and inactivated poliovirus types 1, 2, and 3. By introducing these antigens, the vaccine stimulates the immune system to produce neutralizing antibodies and establish immunological memory, providing long-term protection against the toxins produced by Clostridium tetani and Corynebacterium diphtheriae, the Bordetella pertussis bacterium, and the three serotypes of poliovirus. Common brand names include Repevax and Boostrix-Polio.
- Brand names
- RepevaxBoostrix-PolioAdacel-Polio
- Other names
- diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
02
Targets
Poliovirus capsid proteinsTT (Tetanus toxoid)
Beyond the preview
Go deeper on tetanus-diphtheria-acellular pertussis-inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus-diphtheria-acellular pertussis-inactivated poliovirus vaccine.